Background {#Sec1}
==========

American tegumentary leishmaniasis (ATL) is an infectious disease caused by *Leishmania* protozoan, affecting the skin, oral or nasal mucosa. Brazil is one of 10 countries that together account for 70--75% of the cases of tegumentary leishmaniasis in the world \[[@CR1]\]. *Leishmania amazonensis* and *Leishmania braziliensis* are the main species that cause ATL in Brazil. *L. amazonensis* is associated with the development of localized or diffuse skin lesions whereas *L. braziliensis* is associated with localized cutaneous or mucosal lesions \[[@CR2]--[@CR4]\].

In general, humans or mice infected with *L. braziliensis* present a stronger cellular immune response against the parasites than human or mice infected with *L. amazonensis* \[[@CR5], [@CR6]\]. *L. braziliensis* infections cause small cutaneous lesions that regress after a few weeks in C57BL/6 mice. In these mice, it has been demonstrated that the IL-12-IFN-γ/TNF-α-NO axis controls the parasite infection \[[@CR7]--[@CR9]\]. By contrast, *L. amazonensis* generates chronic and non-healing infection in C57BL/6 mice with a deficient Th1 cell response \[[@CR5], [@CR10]\].

IL-32 is a cytokine expressed by several human cells, including NK cells, monocytes/macrophages, T lymphocytes, epithelial cells, endothelial cells, fibroblasts and hepatocytes. IL-32 is predominantly expressed intracellularly and can induce the production of TNF-α, IL-8 and IL-1β \[[@CR11]\]. To date, there are nine isoforms of human IL-32 and the highest biological activity has been attributed to IL-32γ \[[@CR12]\]. IL-32 is associated with the control or immunopathology of numerous infectious diseases, such as tuberculosis, HIV/AIDS, leprosy and hepatitis \[[@CR13]\] likewise in dermatological diseases \[[@CR14], [@CR15]\].

Although rodents do not naturally produce IL-32, recombinant IL-32 (rIL-32) can activate mouse cells \[[@CR11]\]. In addition, injection of rIL-32γ into the knee joints of mice leads to arthritis partially mediated by induction of TNF-α \[[@CR16]\]. Thus, the use of an experimental animal model to study the role of IL-32 in inflammatory and infectious diseases is made possible by IL-32 humanized transgenic mice.

We previously described that cutaneous and mucosal lesions of patients with ATL caused by *L. braziliensis* exhibit increased IL-32 expression compared to healthy tissues \[[@CR17]\]. Here, we investigated the expression of IL-32 in cutaneous lesions of patients infected with *L. amazonensis*, and the role of IL-32γ in experimental mouse infections caused by *L. amazonensis* and *L. braziliensis*.

Methods {#Sec2}
=======

Patient and control samples {#Sec3}
---------------------------

Patients diagnosed with cutaneous leishmaniasis according to Oliveira et al. \[[@CR8]\] and control healthy individuals were submitted to biopsy procedure to obtain fragments from lesions and healthy skin, after signing the consent form.

Immunohistochemical (IHC) analysis for IL-32 {#Sec4}
--------------------------------------------

Biopsy fragments were obtained from cutaneous lesions to identify *Leishmania* species by polymerase chain reaction (PCR) as previously described \[[@CR8]\], confirming all samples positive for *L. amazonensis*. Samples of healthy skin (*n* = 8) and a fragment of lesions from patients (*n* = 5) were used for IHC analysis for IL-32 using rabbit polyclonal antibodies to human IL-32 (Abcam Inc., Cambridge, UK), according to Galdino et al. \[[@CR17]\]. The tissue expression (epithelium and dermis) of IL-32 was classified as follows: 0, absence of labelled cells; 1, 1--25% of labelled cells; 2, 26--50% of labelled cells; 3, 51--75% of labelled cells; and 4, 76--100% of labelled cells). All sections were blindly analyzed using a light microscope (magnification of 400×).

Animals and parasites {#Sec5}
---------------------

Transgenic mice for human IL-32 were developed by Choi et al. \[[@CR18]\] and donated to our group by Dr. Charles Dinarello (University of Colorado, Denver, USA). Six to 8 week old C57BL/6 WT and IL-32γTg mice were used in the experiments. All procedures were followed in accordance with the guidelines and legislation on ethics research.

*Leishmania* (*L.*) *amazonensis* (MHOM/BR/1973/M2269) and *L.* (*V.*) *braziliensis* (MHOM/BR/2003/IMG) strains were obtained from patients with localized cutaneous lesions \[[@CR19], [@CR20]\]. *L. braziliensis* strain was obtained and identified by our group, as described by Dorta et al. \[[@CR19]\]. Briefly, lesion fragments were macerated in phosphate-buffered saline (PBS) and cultured in Grace's Insect Medium (Gibco, Life Technologies, Carlsbad, USA) supplemented with heat-inactivated 20% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, USA) and 100 U/ml of penicillin/streptomycin (Sigma-Aldrich) at 26 °C. The identification of the species was performed by PCR-RFLP, according to Volpini et al. \[[@CR21]\]. *Leishmania amazonensis* strain was identified and donated to us by Mortara et al. \[[@CR20]\].

*Leishmania amazonensis* and *L. braziliensis* promastigote forms were cultured in Grace's insect medium supplemented as described above. Parasites of either *L. amazonensis* or *L. braziliensis* from stationary phase (6th day) of growth were washed three times with sterile PBS, pH 7.4 (1000×*g*, 10 min, 10 °C), suspended in PBS and quantified by hemocytometer after fixation with PBS/0.1% formaldehyde.

Parasite lysates were obtained by 5 freeze-thaw cycles in liquid nitrogen and 37 °C water bath followed by protein quantification using the Pierce BCA protein assay (ThermoFisher, Rochester, USA).

Infection, disease progression and histopathological analysis {#Sec6}
-------------------------------------------------------------

Animals were inoculated (1 × 10^5^ promastigotes/10 μl of PBS) into the dermis of the left ear. Three independent experiments were performed, with three animals per group in each experiment. Lesion size was measured weekly using a digital caliper. Lesion size is described as the difference between the thickness of the infected ear and the thickness of the uninfected ear \[[@CR22]\]. Tissue parasitism was evaluated in the infected ear, draining lymph node (submandibular) and spleen by limiting dilution assay. The results were expressed as the negative logarithm of the parasite titer \[[@CR23]\]. Paraformaldehyde fixed-ear tissue was embedded in paraffin to be processed for histopathological analysis after haematoxylin and eosin (H&E) staining. The cellular infiltrate evidenced in the inflammatory process was considered \[[@CR24]--[@CR26]\].

Cytokine production {#Sec7}
-------------------

Lesion-draining submandibular lymph node cells from uninfected and infected mice were macerated and maintained in RMPI 1640 medium (Sigma-Aldrich) supplemented with 10% FBS (Gibco), 1 M HEPES (Sigma-Aldrich), 2 mM glutamine (Sigma-Aldrich), 100 U/ml penicillin (Sigma-Aldrich) and 100 μg/ml streptomycin (Sigma-Aldrich). Viable cells were quantified using a hemocytometer by dye exclusion with Trypan blue 0.1% in PBS. Lymph node cells (5 × 10^5^ cells/ml) were stimulated with antigen from *L. amazonensis* or *L. braziliensis* (50 μg/ml) for 24 h or 72 h, at 37 °C and 5% CO~2~. TNF-α and IL-10 were evaluated in the culture supernatants by commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, USA), according to the manufacturer's protocol. IFN-γ was evaluated by ELISA using monoclonal antibodies obtained from hybridoma cultures, according to \[[@CR27]\]. All cultures and measurements were done in duplicates.

Statistical analysis {#Sec8}
--------------------

Data are expressed as means ± standard deviations or median and individual values and compared using Student's *t* or Mann-Whitney U tests, respectively. Analyses were performed using Prism software version 6.0 (GraphPad, San Diego, CA, USA). Significance was established as *P* \< 0.05.

Results {#Sec9}
=======

Expression of IL-32 in lesions of patients with ATL caused by *L. amazonensis* {#Sec10}
------------------------------------------------------------------------------

We previously demonstrated that IL-32 is highly expressed in cutaneous and mucosal lesions of patients with ATL infected with *Leishmania* (*Viannia*) spp., mainly *L. braziliensis*. In addition, amastigote forms of *L. braziliensis* were able to induce IL-32β in human peripheral blood mononuclear cells \[[@CR17]\]. Here, we demonstrate that in cutaneous lesions caused by *L. amazonensis* infection IL-32 protein expression was also increased when compared to healthy skin specimens \[*U* = 7.5, *P* = 0.0412 (epithelium) and *U* = 0.0, *P* = 0.0008 (inflammatory infiltrate)\]. IL-32 was detected both in the epithelium and in the inflammatory infiltrate (Fig. [1a](#Fig1){ref-type="fig"}, b).Fig. 1Expression of IL-32 in American tegumentary leishmaniasis lesions caused by *L. amazonensis*. **a** Fragments of lesions from ATL patients infected with *L. amazonensis* and skin from healthy controls were included in paraffin and submitted to immunohistochemistry for IL-32. The reaction was revealed with 3,3′-Diaminobenzidine and Meyer's hematoxylin used to counterstain. **b** Evaluation of IL-32 expression score was determined according to the percentage of cells expressing IL-32. The scores represent: 0 (absence of stained cells), 1 (1--25% of stained cells), 2 (26--50% stained cells), 3 (51--75% stained cells), and 4 (76--100% stained cells). \**P* \< 0.05 (Mann-Whitney test)

The role of IL-32 in experimental lesions caused by *L. amazonensis* or *L. braziliensis* {#Sec11}
-----------------------------------------------------------------------------------------

To understand the precise role of IL-32 in ATL, we infected human IL-32γTg and WT mice with either *L. amazonensis* or *L. braziliensis*. IL-32γTg mice showed a delayed development of ear lesions caused by *L. amazonensis* (until week 3); however, the size of the lesions were similar to WT mice in later stages of infection (Fig. [2a](#Fig2){ref-type="fig"}, c). In contrast, mice infected with *L. braziliensis* demonstrated a significant increase in the lesion size on the 3rd week of infection (*t* ~(14)~ = 2.23316, *P* = 0.042), as well as a reduction of lesion size from week 6 post-infection in IL-32γTg mice compared to WT mice (Fig. [2b](#Fig2){ref-type="fig"}, c) \[*t* ~(14)~ = 3.29151, *P* = 0.0053 (6 weeks); *t* ~(14)~ = 2.16645, *P* = 0.048 (7 weeks); *t* ~14)~ = 2.82843, *P* = 0.013 (8 weeks); *t* ~(14)~ = 2.37595, *P* = 0.032 (9 weeks)\].Fig. 2IL-32 promotes the control of cutaneous infection caused by *L. braziliensis*, but not caused by *L. amazonensis* in an ear dermis model. WT and IL-32γTg mice were infected in the left ear with 1 × 10^5^ *L. amazonensis* (IFLA/BR/67/PH8) or *L. braziliensis* (MHOM/BR/2003/IMG) promastigotes in the stationary phase of growth (6 days of culture). **a** Ear thickness was monitored weekly, and lesion size was determined by the difference between infected and uninfected ears. **a** *L. amazonensis* infection. **b** *L. braziliensis* infection. **c** Area under the curves is shown for each animal. **d** Ear parasite numbers were determined on week 3, 6 and 9 post-infection with *L. amazonensis* using limiting dilution assays. **e** Lymph node and spleen parasite numbers were determined on week 9 post-infection with *L. amazonensis.* **f** Ear parasite numbers were determined on week 3, 6 and 9 post-infection with *L. braziliensis* using limiting dilution assays. The results presented mean ± standard deviation (8 animals per group). \**P* \< 0.05 (WT × IL-32γTg, Student's *t*-test)

We observed that *L. amazonensis*-infected IL-32γTg mice showed higher lesional parasite load on week 3 of infection compared to WT animals (*t* ~(14)~ = 2.52036, *P* = 0.024). Despite this initial favoring of parasitism in IL-32γTg animals, the growth of *L. amazonensis* in later stages of infection was controlled, whereas parasites grew exponentially in WT mice (Fig. [2d](#Fig2){ref-type="fig"}). Although IL-32γ was not able to reduce the *L. amazonensis* infection in the skin, we observed that IL-32γ is important for parasite dissemination because IL-32γTg mice harbored lower numbers of *L. amazonensis* parasites in draining lymph nodes (*t* ~(6)~ = 3, *P* = 0.024) and spleens (*t* ~(14)~ = 2.46598, *P* = 0.027) compared with WT mice in 9 weeks (Fig. [2e](#Fig2){ref-type="fig"}). During *L. braziliensis* infection, we observed a strong reduction of parasite burden in IL-32γTg mice \[*t* ~(14)~ = 3.68751, *P* = 0.0024 (week 6) and *t* ~(14)~ = 3.12076, *P* = 0.0075 (week 9)\] (Fig. [2f](#Fig2){ref-type="fig"}). We did not observe *L. braziliensis* dissemination until the end of the experiments. As expected, WT and IL-32γTg mice exhibited similar histological profiles of lesional inflammatory infiltrates after *L. amazonensis* infection. In contrast, the inflammatory infiltrate was remarkably reduced on weeks 6 and 9 post-infection in *L. braziliensis*-infected IL-32γTg mice compared to WT mice. Despite this, both WT and IL-32γTg mice showed a reduction of inflammatory infiltrate at the final stage of infection (9 weeks) when comparing the histopathological aspects on 3 or 6 weeks (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Histopathological profiles of ear lesions caused by *L. amazonensis* and *L. braziliensis* in wild-type and IL-32γTg mice. Fragments of ears from C57BL/6 WT and IL-32γTg mice uninfected (above) or infected with *L. amazonensis* (left) or *L. braziliensis* (right) for 3, 6 and 9 weeks were fixed and stained by hematoxylin & eosin, for analysis under a light microscope (100× magnification). A mononuclear cell inflammatory infiltrate was observed in the dermis that was progressive in *L. amazonensis*-infected and regressive in *L. braziliensis*-infected mice. *Scale-bars*: 100 μm

IL-32γ induces inflammatory cytokines in experimental infections caused by *L. braziliensis* in contrast to *L. amazonensis* {#Sec12}
----------------------------------------------------------------------------------------------------------------------------

Lesion-draining submandibular lymph node cells from infected mice were stimulated ex vivo with lysates of *L. amazonensis* or *L. braziliensis* promastigotes for 24 h, or 72 h and cytokines were measured in culture supernatants. No difference in the production of IFN-γ, TNF-α and IL-10 was observed between WT and IL-32γTg animals infected with *L. amazonensis* on weeks 3, 6 or 9 post-infection. In contrast, lymph node cells from *L. braziliensis*-infected IL-32γTg animals showed higher cytokine production after antigen-specific stimulation than cells from WT mice (weeks 3 and 6; Fig. [4](#Fig4){ref-type="fig"}) \[*t* ~(51)~ = 3.22153, *P* = 0.0022 (IFN-γ, 3 weeks); *t* ~(54)~ = 4.87909, *P* \< 0.0001 (TNF-α, 6 weeks); *t* ~(14)~ = 2.92794, *P* = 0.011 (IL-10, 6 weeks)\].Fig. 4IL-32 amplifies the production of inflammatory cytokines induced by *L. braziliensis* during murine ear dermis infection. Lesion-draining submandibular lymph node cells were stimulated with specific antigens from *L. amazonensis* or *L. braziliensis* for 24 h (TNF-α) or 72 h (IFN-γ and IL-10). The production of (**a**) IFN-γ, (**b**) TNF-α and (**c**) IL-10 was evaluated by ELISA in culture supernatants. The results represent the mean ± standard deviation of 8 animals per group. \**P* \< 0.05, (WT × IL-32γTg, Student's t-test)

Discussion {#Sec13}
==========

The present study demonstrated that in addition to *L. braziliensis* \[[@CR17]\], *L. amazonensis* induces a strong IL-32 expression in human cutaneous lesions. Furthermore, we showed that human IL-32γ was able to support the healing of skin lesions in *L. braziliensis*-infected mice, which is in contrast to *L. amazonensis* caused skin lesions. Based on pro-inflammatory properties of IL-32γ \[[@CR11], [@CR13]\] we hypothesize that IL-32γ could increase the immune response against *L. amazonensis* and lead to improved healing of the lesions. Although IL-32γ inhibited the lesional parasite load, IL-32γ did not increase the production of pro-inflammatory cytokines or improved healing. It is well-known that *L. amazonensis* strongly modulates the host immune response against this parasite \[[@CR5], [@CR10], [@CR18], [@CR28]\]. These experimental results, together with the observation that IL-32 is highly expressed in cutaneous lesions of *L. amazonensis*-infected patients, suggest that even in the presence of IL-32 the parasites and lesion are persistent.

Although it is known that C57BL/6 mice are relatively resistant to *L. braziliensis* infection \[[@CR5]\], we observed that the pro-inflammatory response during *L. braziliensis* infection was strengthened by IL-32γ without a significant increase of immunopathology. In addition, IL-32γ played an important role in controlling the parasite load, favoring the healing of the skin lesion. Thus, in cutaneous murine lesions caused by *L. braziliensis* that is restricted to skin and draining lymph node, the pro-inflammatory properties of IL-32γ help the control of the infection. However, in *L. amazonensis,* which spreads beyond the cutaneous lesions to other tissues and suppress cytokine production, IL-32γ contributes to the control of parasite dissemination but not for skin lesion healing. Differential expression of IL-32γ in the tissues during these two infections could explain the results besides intrinsic parasite factors that can interfere with the role of IL-32γ. The results underscore the need of unravelling the molecular mechanisms used by *L. amazonensis* parasites to subvert the antileishmanial effect of IL-32γ in skin observed against *L. braziliensis* infection.

It is important to highlight that murine models of leishmaniasis are not a reliable landscape of the immune responses against *Leishmania* parasites because mice do not produce IL-32. However, murine cells respond to human IL-32 \[[@CR12]\]. Some important microbicidal mechanisms are dependent on IL-32, and therefore these latter mechanisms are lost in mice \[[@CR29]\]. In this way, this IL-32γTg mouse model is very important to reveal novel mechanisms that control or lead to immunopathogenesis in leishmaniasis.

Conclusions {#Sec14}
===========

IL-32γ is an important player in the control of *L. braziliensis* cutaneous infections in contrast to *L. amazonensis-*mediated infections, at least in ear dermis infection model. IL-32γ might be a novel target in strategies to control leishmaniasis caused by *L. braziliensis*.
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